BEHOLD-Ov02

APGOT-OV19: A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Efficacy of GSK5733584 Combined with Bevacizumab Versus Platinum doublet Combined with Bevacizumab in Patients with Platinum-Sensitive Ovarian Cancer.

BEHOLD-Ov022026-09-16T16:12:44+10:00

DESTINY-Ovarian01 | NCT06819007

APGOT-OV13: A Phase 3, Open-label, Multicenter, Randomized Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing, Homologous-Recombination Deficiency Negative Ovarian Cancer.

DESTINY-Ovarian01 | NCT068190072026-09-16T16:25:33+10:00

FRAmework-01 | NCT07213804

APGOT-OV17: FRAmework-01: A Two-Part Phase 3 Study of LY4170156 versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and LY4170156 plus Bevacizumab versus Platinum-Based Chemotherapy plus evacizumab in Platinum-Sensitive Ovarian Cancer.

FRAmework-01 | NCT072138042026-09-16T16:06:16+10:00

RAINFOL-07 | NCT07564141

APGOT-OV21: A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer.

RAINFOL-07 | NCT075641412026-09-16T15:55:18+10:00

RAINFOL-04 | NCT07225270

APGOT-OV18: A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC).

RAINFOL-04 | NCT072252702026-10-14T16:24:53+11:00
Go to Top